Drug Approval | June 06, 2022
FDA publishes ANP’s polymeric drug excipient DMF
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Innate to receive $5M milestone payment from AstraZeneca
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The product will be launched by NATCO's commercial partner Viatris.
Subscribe To Our Newsletter & Stay Updated
